Compounds > tazobactam
Page last updated: 2024-09-03

tazobactam and eravacycline

tazobactam has been researched along with eravacycline in 4 studies

Compound Research Comparison

Studies
(tazobactam)		Trials
(tazobactam)		Recent Studies (post-2010)
(tazobactam)		Studies
(eravacycline)		Trials
(eravacycline)		Recent Studies (post-2010) (eravacycline)
1,32715369495393

Protein Interaction Comparison

ProteinTaxonomytazobactam (IC50)eravacycline (IC50)
30S ribosomal protein S6Escherichia coli K-120.62
30S ribosomal protein S7Escherichia coli K-120.62
50S ribosomal protein L15Escherichia coli K-120.62
50S ribosomal protein L10Escherichia coli K-120.62
50S ribosomal protein L11Escherichia coli K-120.62
50S ribosomal protein L7/L12Escherichia coli K-120.62
50S ribosomal protein L19Escherichia coli K-120.62
50S ribosomal protein L1Escherichia coli K-120.62
50S ribosomal protein L20Escherichia coli K-120.62
50S ribosomal protein L27Escherichia coli K-120.62
50S ribosomal protein L28Escherichia coli K-120.62
50S ribosomal protein L29Escherichia coli K-120.62
50S ribosomal protein L31Escherichia coli K-120.62
50S ribosomal protein L31 type BEscherichia coli K-120.62
50S ribosomal protein L32Escherichia coli K-120.62
50S ribosomal protein L33Escherichia coli K-120.62
50S ribosomal protein L34Escherichia coli K-120.62
50S ribosomal protein L35Escherichia coli K-120.62
50S ribosomal protein L36Escherichia coli K-120.62
30S ribosomal protein S10Escherichia coli K-120.62
30S ribosomal protein S11Escherichia coli K-120.62
30S ribosomal protein S12Escherichia coli K-120.62
30S ribosomal protein S13Escherichia coli K-120.62
30S ribosomal protein S16Escherichia coli K-120.62
30S ribosomal protein S18Escherichia coli K-120.62
30S ribosomal protein S19Escherichia coli K-120.62
30S ribosomal protein S20Escherichia coli K-120.62
30S ribosomal protein S2Escherichia coli K-120.62
30S ribosomal protein S3Escherichia coli K-120.62
30S ribosomal protein S4Escherichia coli K-120.62
30S ribosomal protein S5Escherichia coli K-120.62
30S ribosomal protein S8Escherichia coli K-120.62
30S ribosomal protein S9Escherichia coli K-120.62
50S ribosomal protein L13Escherichia coli K-120.62
50S ribosomal protein L14Escherichia coli K-120.62
50S ribosomal protein L16Escherichia coli K-120.62
50S ribosomal protein L23Escherichia coli K-120.62
30S ribosomal protein S15Escherichia coli K-120.62
50S ribosomal protein L17Escherichia coli K-120.62
50S ribosomal protein L21Escherichia coli K-120.62
50S ribosomal protein L30Escherichia coli K-120.62
50S ribosomal protein L6Escherichia coli K-120.62
30S ribosomal protein S14Escherichia coli K-120.62
30S ribosomal protein S17Escherichia coli K-120.62
30S ribosomal protein S1Escherichia coli K-120.62
50S ribosomal protein L18Escherichia coli K-120.62
50S ribosomal protein L2Escherichia coli K-120.62
50S ribosomal protein L3Escherichia coli K-120.62
50S ribosomal protein L24Escherichia coli K-120.62
50S ribosomal protein L4Escherichia coli K-120.62
50S ribosomal protein L22Escherichia coli K-120.62
50S ribosomal protein L5Escherichia coli K-120.62
30S ribosomal protein S21Escherichia coli K-120.62
50S ribosomal protein L25Escherichia coli K-120.62
50S ribosomal protein L36 2Escherichia coli K-120.62

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's4 (100.00)2.80

Authors

AuthorsStudies
Bassetti, M; Battaglini, D; Giacobbe, DR; Pelosi, P; Vena, A1
Garcia, JA; Liang, SY; Long, B; Matlock, A; Moussavi, K1
Deng, T; Kong, W; Li, S; Shu, Y; Wu, Y1
Chen, TY; Hsu, CK; Lai, CC; Shih, SC; Tang, HJ; Weng, TS1

Reviews

4 review(s) available for tazobactam and eravacycline

ArticleYear
The role of new antimicrobials for Gram-negative infections in daily clinical practice.
    Current opinion in infectious diseases, 2020, Volume: 33, Issue:6

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactams; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxins; Sisomicin; Tazobactam; Tetracyclines

2020
Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections.
    Internal and emergency medicine, 2021, Volume: 16, Issue:8

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Design; Drug Resistance, Multiple; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Humans; Meropenem; Sisomicin; Tazobactam; Tetracyclines

2021
Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
    BMC infectious diseases, 2023, Apr-21, Volume: 23, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Cefepime; Humans; Intraabdominal Infections; Meropenem; Metronidazole; Network Meta-Analysis; Tazobactam; Tigecycline

2023
Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: a systematic review and meta-analysis of randomized controlled trials.
    International journal of antimicrobial agents, 2023, Volume: 62, Issue:2

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Drug Combinations; Humans; Intraabdominal Infections; Randomized Controlled Trials as Topic; Tazobactam

2023